Remdesivir in the COVID-19 Pandemic: An Analysis of Spontaneous Reports in VigiBase During 2020

INTRODUCTION: The safety profile of remdesivir, conditionally approved for COVID-19, was limited at its 2020 introduction. Adverse drug reactions (ADRs) for medicines are collected in VigiBase, the WHO Global Database of Individual Case Safety Reports (ICSRs). OBJECTIVE: This study aimed to provide...

Descripción completa

Detalles Bibliográficos
Autores principales: Rocca, Elena, Gauffin, Oskar, Savage, Ruth, Vidlin, Sara Hedfors, Grundmark, Birgitta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8353611/
https://www.ncbi.nlm.nih.gov/pubmed/34374967
http://dx.doi.org/10.1007/s40264-021-01091-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8353611/
https://www.ncbi.nlm.nih.gov/pubmed/34374967
http://dx.doi.org/10.1007/s40264-021-01091-x

Ejemplares similares